Key Takeaways Tempus AI acquired Paige for $81.25M, gaining 7M pathology images and FDA-cleared AI tools.The Deep 6 AI deal expanded Tempus' reach to 30M patient records across 750 healthcare providers.Ambry Genetics' acquisition broadened Tempus' AI-driven offerings into genetics and multiple specialties.Last Friday, Tempus AI, Inc. (TEM) announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition, valued at $81.25 million, is expected to allow Tempus to grow its da ...

Key Takeaways Tempus AI nearly doubled revenues in Q2 2025, led by strong genomics and data services growth.Butterfly posted modest gains but secured a major enterprise deal and preps Compass AI launch.Analysts see 128% upside for BFLY, while TEM's target implies an 8.1% decline from its last close.Tempus AI (TEM) and Butterfly Network (BFLY) both just reported their respective second-quarter 2025 results, which shed light on their AI-driven trajectories. Tempus AI continues to post rapid top-line expansion ...

Core Insights - The artificial intelligence (AI) revolution is significantly impacting various industries, with healthcare being one of the sectors that is beginning to adopt AI technologies [1][2][3] Group 1: AI in Healthcare - Despite the slow adoption of AI in healthcare, there are promising opportunities for investors as companies begin to commercialize AI solutions [3] - Recursion Pharmaceuticals has developed Recursion OS, a platform that utilizes 36 petabytes of biological and chemical data to virtually test drug potentials at a fraction of the cost of traditional clinical trials [7][9] - Tempus AI offers practical AI solutions for caregivers, helping with disease diagnosis, clinical trial suggestions, and treatment efficacy predictions, which enhances patient outcomes [15][16] Group 2: Company Performance - Recursion Pharmaceuticals reported a revenue of just under $34 million in the first half of the year, with a net loss of $374 million, but analysts expect revenue to triple by 2027 while halving losses [11][12] - Tempus AI generated $693 million in revenue last year, reflecting a 30% year-over-year growth, and is projected to become profitable by fiscal 2027 as it continues to grow [14][18]

Key Takeaways Boston Scientific leverages AI in heart diagnostics, arrhythmia mapping and coronary imaging.Johnson & Johnson integrates AI in robotic surgery, digital analytics and connected operating rooms.GE HealthCare and Tempus AI advance AI-powered imaging, precision medicine and clinical decision tools.Rising demand for precision and personalized medicine has significantly augmented the need for artificial intelligence (AI)-enabled medical devices to deliver highly individualized diagnostics and treat ...

Group 1: Market Overview - Five stocks are highlighted for potential buying opportunities before November, driven by high short-interest and strong market fundamentals [1] - These companies are positioned within the AI revolution, expected to achieve market-leading growth and improved shareholder value over the next five to ten years [2] Group 2: SoundHound AI - SoundHound AI (NASDAQ: SOUN) has a current price of $12.38, with a 52-week range of $4.32 to $24.98 and a price target of $13.36 [3] - The stock has a high short interest of 33% of the float, despite a 7% decrease in short interest at the end of July [3] - The company has shown hyper-growth exceeding 200% due to expanding verticals and client counts, although growth concerns remain [4] - Analyst consensus is a Moderate Buy, with price target revisions suggesting a potential rise to the $18 range [5] Group 3: AST SpaceMobile - AST SpaceMobile (NASDAQ: ASTS) is currently priced at $43.93, with a 52-week range of $17.50 to $60.95 and a price target of $48.41 [8] - The stock has a short interest of approximately 30% of the float, with bullish analyst trends supporting rising price action [8] - The price target has increased by about 100% over the past 12 months, with potential to reach an all-time high of $63 [9] - ASTS is positioned to become a global leader in mobile services, driving significant growth and profitability [10] Group 4: Symbotic - Symbotic (NASDAQ: SYM) is priced at $43.53, with a 52-week range of $16.32 to $64.16 and a price target of $42.69 [13] - The stock has a short interest of 30%, down 10% from the previous report, but still near record levels [13] - Despite a Hold rating, increased coverage and a bullish price target outlook suggest potential for a 20% to 25% upside [14] Group 5: NuScale Power - NuScale Power (NYSE: SMR) is currently priced at $32.20, with a 52-week range of $6.88 to $53.50 and a price target of $34.44 [16] - The stock has a short interest of 22%, with a significant pullback following its Q2 release [17] - Analyst trends are bullish, with a price target expected to rise to $46, reflecting a more than 300% increase over the past year [18] - The MACD convergence indicates potential for a market rebound [19] Group 6: Tempus AI - Tempus AI (NASDAQ: TEM) is priced at $68.39, with a 52-week range of $31.36 to $91.45 and a price target of $67.64 [22] - The stock has a short interest of 25%, down 36% from the prior month, but still elevated [22] - Analysts rate Tempus AI as a Moderate Buy, forecasting an 80% revenue growth pace in Q3 [23]

Core Insights - Tempus AI, Inc. (TEM) is rapidly expanding its partnerships in oncology and neuroscience, utilizing its AI platforms, Lens and Next, to enhance precision medicine [1] Partnerships and Collaborations - Tempus has initiated a multi-year collaboration with The Abrams Research Center at Northwestern University to utilize its AI-powered Lens platform for genomic data analysis in Alzheimer's research [2] - In February, Tempus partnered with the Institute for Follicular Lymphoma Innovation to create a deidentified data library in Lens, aimed at accelerating treatment development for follicular lymphoma [2] - In May, Tempus formed a strategic collaboration with Boehringer Ingelheim to advance cancer pipeline research, building on previous joint efforts [3] - Earlier this year, Tempus and Stemline Therapeutics announced a collaboration to enhance oncology treatments using the AI-enabled Next platform [3] - In January, Tempus partnered with Genialis to leverage its multimodal dataset for developing new RNA-based algorithms across various cancer types [4] Industry Comparisons - Sophia Genetics expanded its partnership with AstraZeneca to utilize its AI Factories for breast cancer therapy research, while also collaborating with Result Laboratorium for pharmacogenomics insights [5] - AbbVie announced collaborations with ADARx Pharmaceuticals and Gubra A/S to develop therapeutics across multiple disease areas, including oncology [6] Stock Performance - Over the past year, Tempus AI shares have increased by 35.9%, outperforming the industry growth of 21.4% and the S&P 500's 15.9% improvement [7] Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 9.38, significantly higher than the industry average of 5.87 [10] Earnings Estimates - Recent estimates for Tempus AI's loss per share have shown mixed movements for 2025 and 2026, with current estimates at -0.16 for Q3 2025 and -0.70 for the current year [11][12]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Tempus AI, Inc. following a class action complaint that alleges breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2]. - Concerns were raised regarding the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2]. - These issues collectively indicate weaknesses in Tempus' core operations and revenue prospects [2]. Group 2: Financial Impact - Following the release of a report by Spruce Point Capital Management that raised significant concerns about Tempus' management and financial reporting, the stock price of Tempus fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [3][4]. Group 3: Legal and Contact Information - Long-term stockholders of Tempus are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims [1][5]. - The law firm specializes in representing individual and institutional investors in complex litigation across various courts [6].

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI NASDAQ: TEM. In a world where healthcare IPOs are typically dominated by biotech companies that generate little to no revenue, Tempus stands out. Tempus AI TodayTEMTempus AI$69.63 +3.29 (+4.96%) 52-Week Range$31.36▼$91.45Price Target$65.36Add to WatchlistThe firm has posted sales of approximately $952 million over the last twelve months and has made strong improvements in profitability. The s ...

Core Insights - Tempus AI's stock has increased nearly 13% since the release of its second-quarter 2025 earnings, driven by strong revenue growth and strategic positioning in a high-value market [1] - The company reported an 89.6% year-over-year revenue increase, primarily due to a significant rise in Genomics revenues and growth in its Data and Services segment [1][6] - Gross profit more than doubled, and adjusted EBITDA losses narrowed, indicating a clear path to profitability [2][6] Financial Performance - Revenues rose 89.6% year over year, surpassing the Zacks Consensus Estimate by 5.12%, with Genomics revenues surging by 115% and Data and Services increasing by 35.7% [6][9] - Adjusted operating expenses decreased by 57.8%, leading to a reduction in adjusted EBITDA losses to $5.6 million from $31.2 million a year ago [7][9] - The company has raised its full-year revenue guidance and strengthened liquidity through a $750 million convertible note offering [2][8] Market Position - In August, Tempus AI's shares surged 17.3%, outperforming the Medical Info Systems industry, which declined by 3% [3] - The stock is trading above its 50-day and 200-day moving averages, indicating upward momentum and price stability [10] - Despite strong performance, the stock is currently overvalued compared to its industry, with a forward price-to-sales ratio of 7.98, higher than the industry average of 5.57 [12] Future Outlook - Tempus AI is positioned to achieve sustainable profitability soon, supported by high-margin revenue growth and disciplined cost control [8][13] - Management has reaffirmed its $5 million adjusted EBITDA target for 2025, representing a $110 million improvement over 2024 [7] - The company's ability to maintain growth momentum and control costs will be crucial for its path to sustained profitability [13]

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Tempus between August 6, 2024 and May 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, ...